Mashema vs Ozempic: Comparison Guide

Mashema vs Ozempic: Comparison Guide

If you have come across both Mashema and Ozempic, it is easy to assume they belong to different drug classes. In the Indian market, though, the more accurate comparison is between two semaglutide brands rather than between semaglutide and an entirely different incretin medicine.

This guide compares Mashema and Ozempic in plain language so you can discuss them more confidently with your doctor. Consult your healthcare provider before starting any medication.

Understanding Ozempic

Ozempic is Novo Nordisk’s brand for semaglutide, a GLP-1 receptor agonist. It is commonly used in adults with type 2 diabetes and is also widely discussed because semaglutide can reduce appetite and support weight change in some patients.

Semaglutide helps the body regulate blood sugar, slows gastric emptying, and can increase feelings of fullness. Ozempic is taken as a once-weekly injection.

What is Mashema?

Mashema is associated with Zydus and is also a semaglutide brand in India. Zydus announced Mashema as one of its semaglutide injection brands for the Indian market, alongside other brand names built on the same active ingredient.

That is why Mashema should be discussed within the semaglutide category in this comparison, not as a separate dual-pathway incretin therapy.

What they have in common

Mashema and Ozempic share the same core active ingredient: semaglutide.

That means both are discussed in relation to the same general therapeutic effects:

• better glucose control in type 2 diabetes
• slower stomach emptying
• reduced appetite in many users
• once-weekly injection routines

They also share a similar practical conversation around dose escalation, injection-day planning, and gastrointestinal side effects.

Key differences: Mashema vs Ozempic

1. Manufacturer and brand identity

• Ozempic is made by Novo Nordisk.
• Mashema is associated with Zydus in India.

2. Indian-market positioning

Ozempic is the globally established originator semaglutide brand. Mashema is part of the newer India-market rollout of semaglutide by a domestic manufacturer.

For patients, that may influence:

• what brand is available locally
• the pen system or cartridge workflow
• pricing and refill logistics
• how your clinician frames the choice

3. Device and access experience

Zydus described its semaglutide launch as using a reusable pen device across its semaglutide brands. Ozempic has its own established pen system. Even when the active drug is the same, the delivery experience can still differ.

4. Evidence base

The best-known large semaglutide trial data are generally tied to the originator semaglutide evidence base. In practice, clinicians comparing Mashema and Ozempic still interpret both through the broader semaglutide data landscape, while also accounting for local product details and approval context.

Side effects and tolerability

Because both brands are semaglutide-based, the expected side-effect pattern is broadly similar. Common side effects may include:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• lower appetite

Side effects often feel strongest early on or after dose increases, which is why dose titration and follow-up matter.

Questions to ask your doctor

If your doctor mentions either Mashema or Ozempic, ask:

1. Which exact semaglutide brand are you prescribing?
2. What dose should I start with, and when does it increase?
3. Which pen device will I be using?
4. What side effects should I watch for in the first month?
5. Is local availability likely to affect refills?

Bottom line

Mashema and Ozempic are not a semaglutide-versus-different-drug-class comparison. In India, Mashema is better understood as a Zydus semaglutide brand, while Ozempic is Novo Nordisk’s semaglutide brand. The core medicine is the same, but manufacturer, device, access, and local market context may differ.

Your clinician can help you compare those differences in a way that fits your diagnosis, goals, and prescription plan. Consult your healthcare provider before starting any medication.

Sources

• https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-plans-to-launch-innovative-Semaglutide-Injection-in-India-on-Day-1-of-patent-expiry--expanding-patient-access-to-GLP-1-therapy.pdf
• https://www.novo-pi.com/ozempic.pdf
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1